This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ICPT Intercept Pharmaceuticals (ICPT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Intercept Pharmaceuticals Stock (NASDAQ:ICPT) Get ICPT alerts:Sign Up Key Stats Today's Range$19.00▼$19.0050-Day Range$18.20▼$19.0052-Week Range$8.82▼$21.86VolumeN/AAverage Volume1.36 million shsMarket Capitalization$794.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A.. Read More Receive ICPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ICPT Stock News HeadlinesIntercept Pharma pulls liver disease drug from US after regulator's requestSeptember 11, 2025 | msn.comIntercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical ...September 11, 2025 | markets.businessinsider.comJ.P. Morgan is betting on this coinWhile crypto trades sideways on Iran uncertainty and mixed economic signals... the world's largest bank isn't waiting for clarity. J.P. Morgan is already building production-level infrastructure on one specific blockchain. Not Bitcoin. Not Ethereum. Not Solana. A coin most retail investors have never heard of. In January, this coin's new supply was cut in half. Every transaction permanently destroys coins. Institutional volume is about to surge... while supply gets squeezed from both ends. With the market chopping sideways and most investors frozen... this is exactly when the biggest positions get built.August 4 at 1:00 AM | Crypto 101 Media (Ad)Intercept Pharma withdraws liver disease drug from US marketSeptember 11, 2025 | reuters.comIntercept Announces Data to be Presented at Digestive Disease Week 2025April 30, 2025 | finance.yahoo.comIntercept loses Ocaliva FDA full approval bid in rare liver diseaseNovember 13, 2024 | msn.comUS FDA declines full approval for Intercept's liver disease drugNovember 12, 2024 | reuters.comIntercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)November 12, 2024 | globenewswire.comSee More Headlines ICPT Stock Analysis - Frequently Asked Questions How were Intercept Pharmaceuticals' earnings last quarter? Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.42. The firm's revenue was up 16.6% compared to the same quarter last year. Read the conference call transcript. When did Intercept Pharmaceuticals IPO? Intercept Pharmaceuticals (ICPT) raised $70 million in an initial public offering (IPO) on Thursday, October 11th 2012. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. What other stocks do shareholders of Intercept Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intercept Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Sarepta Therapeutics (SRPT), Netflix (NFLX), Advanced Micro Devices (AMD) and Alibaba Group (BABA). Company Calendar Last Earnings8/02/2023Today8/04/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ICPT CIK1270073 Webwww.interceptpharma.com Phone(646) 747-1000Fax646-747-1001Employees341Year Founded2002Profitability EPS (Trailing Twelve Months)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$221.82 million Net Margins-19.39% Pretax Margin-18.09% Return on Equity-77.48% Return on Assets-11.99% Debt Debt-to-Equity Ratio3.12 Current Ratio4.22 Quick Ratio2.52 Sales & Book Value Annual Sales$285.71 million Price / Sales2.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book11.05Miscellaneous Outstanding Shares41,830,000Free Float39,192,000Market Cap$794.77 million OptionableNo Data Beta0.88 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ICPT) was last updated on 8/4/2026 by MarketBeat.com Staff. From Our Partners"Second Wave” Hitting Iran Soon? Wall Street Issues WarningAnalysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...TradeSmith | SponsoredJ.P. Morgan is betting on this coinWhile crypto trades sideways on Iran uncertainty and mixed economic signals... the world's largest bank isn't ...Crypto 101 Media | Sponsored7 Bankers Met in Secret (Now We Pay for It)A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in se...Decentralized Masters | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored[URGENT] Mode Mobile terms changing Aug 14Mode Mobile has secured its Nasdaq ticker, $MODE, while still in the pre-IPO stage. More than 60,000 investors...Mode Mobile | Sponsored1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...Chaikin Analytics | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredThey Crashed the Dollar 40% Before. It's Happening Again.In 1985, world powers deliberately drove the dollar lower in a coordinated deal that drained everyday savers. ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intercept Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intercept Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
